Source comparison
Tesamorelin vs Egrifta SV Mechanism: Clinical Comparison
Active peptide sequence 44-amino-acid GHRH analogue Identical 44-amino-acid sequence Pharmacodynamically equivalent. Same receptor binding and GH release profile Mechanism of action GHRHR agonism → pulsatile GH secretion → VAT lipolysis Identical pathway No me
This comparison does not assign a generated winner or score.
- Active peptide sequence
- 44-amino-acid GHRH analogue
- Identical 44-amino-acid sequence
- Pharmacodynamically equivalent. Same receptor binding and GH release profile
- Mechanism of action
- GHRHR agonism → pulsatile GH secretion → VAT lipolysis
- Identical pathway
- No mechanistic difference. Both operate through endogenous GH stimulation
- Dose per injection
- 2mg tesamorelin in 0.5mL after reconstitution
- 2mg tesamorelin in 0.5mL pre-mixed
- Dose equivalence confirmed by FDA bioequivalence studies
- Reconstitution requirement
- Daily mixing with bacteriostatic water required
- None. Ready-to-use liquid
- Egrifta SV reduces user error and contamination risk in protocol adherence
- Post-reconstitution stability
- 3–5 days refrigerated (2–8°C)
- 30 days refrigerated (2–8°C)
- Liquid formulation extends usable shelf life 6–10×
- Storage before use
- Room temperature stable as lyophilized powder
- Refrigeration required throughout
- Lyophilized form offers easier transport; liquid form requires cold chain
- Onset of GH release
- 30–60 minutes post-injection
- Identical kinetics
- No pharmacokinetic difference. Both produce equivalent GH peaks
- VAT reduction magnitude
- 15.2% at 26 weeks (REDUCE trial)
- 15.8% at 26 weeks (EMERGE trial)
- Statistically equivalent efficacy. Formulation doesn't alter clinical outcome
- Bottom Line
- Original formulation with proven efficacy but higher logistical complexity
- Bioequivalent reformulation optimized for ease of use. Same mechanism, simpler execution
- Choose based on storage constraints and protocol complexity, not efficacy expectations